Tetroxoprim
Chemical compound
- J01EE06 (WHO) (with sulfadiazine)
- 5-[3,5-Dimethoxy-4-(2-methoxyethoxy)benzyl]pyrimidine-2,4-diamine
- 53808-87-0
Y
- 65450
- 58910
N
- 5R6712AY0K
- D06097 Y
- ChEMBL32039 N
- DTXSID80202085
- Interactive image
- COCCOC1=C(C=C(C=C1OC)CC2=CN=C(N=C2N)N)OC
InChI
- InChI=1S/C16H22N4O4/c1-21-4-5-24-14-12(22-2)7-10(8-13(14)23-3)6-11-9-19-16(18)20-15(11)17/h7-9H,4-6H2,1-3H3,(H4,17,18,19,20)N
- Key:WSWJIZXMAUYHOE-UHFFFAOYSA-NN
N
Y (what is this?) (verify)Tetroxoprim (INN) is a derivative of trimethoprim. It was first described in 1979.[1][2][3]
Its chemical formula is C=16 | H=22 | N=4 | O=4. [2][3]
References
- ^ Aschhoff HS, Vergin H (November 1979). "Tetroxoprim—a new inhibitor of bacterial dihydrofolate reductase". J Antimicrob Chemother. 5 (B): 19–25. doi:10.1093/jac/5.supplement_b.19. PMID 43863.
- ^ a b "Tetroxoprim". pubchem.ncbi.nlm.nih.gov.
- ^ a b "Tetroxoprim - an overview | ScienceDirect Topics". www.sciencedirect.com.
- v
- t
- e
(inhibit bacterial
purine metabolism,
thereby inhibiting
DNA and RNA
synthesis)
| DHFR inhibitor |
| ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Sulfonamides (DHPS inhibitor) |
| ||||||||
| Combinations |
| ||||||||
| Other DHPS inhibitors |
(inhibit bacterial
topoisomerase
and/or DNA gyrase,
thereby inhibiting
DNA replication)
| 1st generation | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Fluoroquinolones |
| ||||||||
| Newer non-fluorinated | |||||||||
| Related (DG) |
inhibitors
| Nitroimidazole derivatives | |
|---|---|
| Nitrofuran derivatives |
| Rifamycins/ RNA polymerase | |
|---|---|
| Lipiarmycins |
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
 | This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
